Statistical Data

Josef M. Issels, M.D. reported in "Immunotherapy in Progressive Metastatic Cancer, A Fifteen Year Survival Follow-up" Clinical Trials Journal (London) 1970. 7, NO. 3, A Peer Review Paper, pp. 357-366, that of 370 patients with various cancers who were given the Issels Treatment shortly after surgery or irradiation, 322 (87%) were alive and well after five years without relapse or detectable metastases. A restoration of the immune functions can reduce the incidence of relapse from about 50% (World Statistic) to 13% by combined conventional treatments and comprehensive immunotherapy.

John Anderson, M.D., Teaching Professor at King's College Hospital, London, reported 17% cures of histologically verified metastatic malignomas by the Issels Treatment. The independent randomized study comprised 570 patients with various cancers after all conventional methods were exhausted (General Practitioner, March 1971, pp. 15-16, London).

An independent statistical study by A.G. Audier, M.D., University of Leiden, Holland "Immunotherapie Metastasierender Malignome" Die Medizinische 1959, NO. 40, A Peer Review Paper, pp. 1860-64, reported a 16.6% cure rate of histologically verified metastatic malignomas by the Issels Treatment. The study comprised 252 patients with various cancers after all conventional methods were exhausted (world wide cure rate is 2%)

DISCLAIMER: The extent of the response to treatment varies from patient to patient, even with similar diagnosis as the internal bodily environment is unique to each individual patient.

>>> For ADDITIONAL INFORMATION on Treatment and Costs please click here or call 1.888.447.7357

>> Back to top

The Department of Epidemiology, Mailman School of Public Health, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons at Columbia University, New York did a best case study at the Hufeland clinic of Dr. Josef Issels’ successor in Germany, Dr. Wolfgang Woeppel, M.D. (08.15.1946 –07.10.2006). The abstract of the publication is quoted below.

Integr Cancer Ther. 2005 Jun;4(2):156-67. [Link to the Publication.]

Cancer Outcomes at the Hufeland (Complementary/Alternative Medicine) Klinik: A Best-Case Series Review.

Jacobson JS, Grann VR, Gnatt MA, Hibshoosh H, Austin JH, Millar WS, Neugut AI.

Department of Epidemiology, Mailman School of Public Health, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons.

PURPOSE: A best-case series review is an efficient tool with which to screen complex complementary and alternative treatments for cancer as candidates for further study. STUDY DESIGN: The National Cancer Institute and other agencies have adopted the best-case series method to evaluate cancer treatments involving complementary and alternative medicine (CAM) for further study. The authors conducted a best-case series review of the Hufeland Klinik. Established in 1985 in Bad Mergentheim, Germany, this facility treats more than 500 cancer patients per year. Hufeland treatment includes dietary modification, injections, ozone therapy, active fever therapy, psychotherapy, and sometimes hormone therapy and/or low-dose chemotherapy. The goal of the treatment is to prolong survival and to maintain good quality of life. METHODS: The clinic provided summaries of 27 cases in which patients with longer than expected survival had agreed to make their medical records available for review. The review involved pathologic confirmation of disease and radiologic confirmation of complete response (CR) or partial response (PR) not attributable to conventional treatment. RESULTS: Based on the summaries and an exhaustive 2-year search for medical records, slides, and imaging data, 12 of 27 cases were selected for full review, and 5 (3 CRs and 2 PRs) were judged best cases. CONCLUSION: Most patients with common cancers receive conventional treatment before coming to Hufeland, and many are treated with chemotherapy and/or hormonal therapy while there. Hence, only a few could be considered for review. With 5 of 12 patients showing a treatment response, the authors conclude that the Hufeland treatment merits further study. They also recommend the development of criteria with which to evaluate best-case series reviews of complex CAM treatments for patients with advanced cancer.

PMID: 15911928 [PubMed - in process]

>>> For ADDITIONAL INFORMATION on Treatment and Costs please click here or call 1.888.447.7357